• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Effect of finerenone in patients with diabetes and advanced chronic kidney disease.

作者信息

Mori Daisuke, Tamai Shinjiro, Nomi Hiroki, Nagatoya Katsuyuki, Yamauchi Atsushi

机构信息

Department of Nephrology, Osaka Rosai Hospital, 1179-3 Nagasone, Sakai, Osaka, 591-8025, Japan.

出版信息

J Nephrol. 2025 Mar 1. doi: 10.1007/s40620-025-02244-2.

DOI:10.1007/s40620-025-02244-2
PMID:40025397
Abstract
摘要

相似文献

1
Effect of finerenone in patients with diabetes and advanced chronic kidney disease.非奈利酮对糖尿病合并晚期慢性肾脏病患者的影响。
J Nephrol. 2025 Mar 1. doi: 10.1007/s40620-025-02244-2.
2
Efficacy and Safety of Finerenone in Asian Patients with Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Analysis.非奈利酮在亚洲2型糖尿病合并慢性肾脏病患者中的疗效与安全性：一项FIDELITY分析
Kidney Dis (Basel). 2025 May 22;11(1):402-415. doi: 10.1159/000545415. eCollection 2025 Jan-Dec.
3
Cost-effectiveness of treatment with finerenone in mild to advanced stage chronic kidney disease patients with type 2 diabetes from a societal perspective.从社会角度看，非奈利酮治疗2型糖尿病轻度至重度慢性肾病患者的成本效益。
BMJ Public Health. 2025 Jun 25;3(1):e001288. doi: 10.1136/bmjph-2024-001288. eCollection 2025.
4
Finerenone and Kidney Outcomes in Patients With Heart Failure: The FINEARTS-HF Trial.非奈利酮与心力衰竭患者的肾脏结局：FINEARTS-HF试验
J Am Coll Cardiol. 2025 Jan 21;85(2):159-168. doi: 10.1016/j.jacc.2024.10.091. Epub 2024 Oct 25.
5
Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes.非奈利酮与恩格列净治疗慢性肾脏病合并2型糖尿病
N Engl J Med. 2025 Aug 7;393(6):533-543. doi: 10.1056/NEJMoa2410659. Epub 2025 Jun 5.
6
COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics.使用尿白蛋白肌酐比值（UACR）终点的非奈利酮与恩格列净联合治疗慢性肾脏病合并2型糖尿病患者的疗效（CONFIDENCE）试验：基线临床特征
Nephrol Dial Transplant. 2025 Aug 1;40(8):1559-1569. doi: 10.1093/ndt/gfaf022.
7
Cardiorenal Benefits of Finerenone in Different Races and Kidney Function in Patients with Chronic Kidney Disease.在慢性肾脏病患者中，不同种族和肾功能下非奈利酮的心脏肾脏获益。
Cardiorenal Med. 2024;14(1):227-234. doi: 10.1159/000538347. Epub 2024 Mar 27.
8
The role of finerenone in the concomitant management of chronic kidney disease-type 2 diabetes and the implication for heart failure prevention and treatment.非奈利酮在慢性肾脏病合并2型糖尿病综合管理中的作用以及对心力衰竭预防和治疗的意义。
Heart Fail Rev. 2025 May 31. doi: 10.1007/s10741-025-10520-3.
9
Early Efficacy and Safety of Finerenone on Type 2 Diabetes-Related Chronic Kidney Disease: A Real-World Observational Study in China.非奈利酮治疗2型糖尿病相关慢性肾脏病的早期疗效与安全性：一项中国真实世界观察性研究
Diabetes Metab Res Rev. 2025 Sep;41(6):e70078. doi: 10.1002/dmrr.70078.
10
Finerenone in diabetic kidney disease: A systematic review and critical appraisal.非奈利酮治疗糖尿病肾病：系统评价与批判性评价。
Diabetes Metab Syndr. 2022 Oct;16(10):102638. doi: 10.1016/j.dsx.2022.102638. Epub 2022 Oct 4.

本文引用的文献

1
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.在 2 型糖尿病合并慢性肾脏病患者中，用非奈利酮治疗的心血管和肾脏结局：FIDELITY 汇总分析。
Eur Heart J. 2022 Feb 10;43(6):474-484. doi: 10.1093/eurheartj/ehab777.
2
Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease.糖尿病肾病中的盐皮质激素受体拮抗剂
Front Pharmacol. 2021 Oct 28;12:754239. doi: 10.3389/fphar.2021.754239. eCollection 2021.
3
Mineralocorticoid Receptor Antagonism in Chronic Kidney Disease.
慢性肾脏病中的盐皮质激素受体拮抗作用
Kidney Int Rep. 2021 Jun 10;6(9):2281-2291. doi: 10.1016/j.ekir.2021.05.027. eCollection 2021 Sep.
4
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.在肾脏病和 2 型糖尿病患者中用非奈利酮发生的心血管事件。
N Engl J Med. 2021 Dec 9;385(24):2252-2263. doi: 10.1056/NEJMoa2110956. Epub 2021 Aug 28.
5
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.非奈利酮对 2 型糖尿病患者慢性肾脏病结局的影响。
N Engl J Med. 2020 Dec 3;383(23):2219-2229. doi: 10.1056/NEJMoa2025845. Epub 2020 Oct 23.
6
Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine.甾体和非甾体盐皮质激素受体拮抗剂在心脏肾脏医学中的应用。
Eur Heart J. 2021 Jan 7;42(2):152-161. doi: 10.1093/eurheartj/ehaa736.